Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,902 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
Fidler S, Stöhr W, Pace M, Dorrell L, Lever A, Pett S, Kinloch-de Loes S, Fox J, Clarke A, Nelson M, Thornhill J, Khan M, Fun A, Bandara M, Kelly D, Kopycinski J, Hanke T, Yang H, Bennett R, Johnson M, Howell B, Barnard R, Wu G, Kaye S, Wills M, Babiker A, Frater J; RIVER trial study group. Fidler S, et al. Among authors: clarke a. Lancet. 2020 Mar 14;395(10227):888-898. doi: 10.1016/S0140-6736(19)32990-3. Epub 2020 Feb 19. Lancet. 2020. PMID: 32085823 Clinical Trial.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team. Sax PE, et al. Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15. Lancet. 2015. PMID: 25890673 Clinical Trial.
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie N, Bowman C, Lacey CJ, Apea V, Brady M, Fox J, Taylor S, Antonucci S, Khoo SH, Rooney J, Nardone A, Fisher M, McOwan A, Phillips AN, Johnson AM, Gazzard B, Gill ON. McCormack S, et al. Among authors: clarke a. Lancet. 2016 Jan 2;387(10013):53-60. doi: 10.1016/S0140-6736(15)00056-2. Epub 2015 Sep 9. Lancet. 2016. PMID: 26364263 Free PMC article. Clinical Trial.
Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues.
Antinori A, Clarke A, Svedhem-Johansson V, Arribas JR, Arenas-Pinto A, Fehr J, Gerstoft J, Horban A, Clotet B, Ripamonti D, Girard PM, Hill AM, Moecklinghoff C. Antinori A, et al. Among authors: clarke a. AIDS. 2015 Sep 10;29(14):1811-20. doi: 10.1097/QAD.0000000000000778. AIDS. 2015. PMID: 26372387 Free article. Clinical Trial.
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.
Dolling DI, Desai M, McOwan A, Gilson R, Clarke A, Fisher M, Schembri G, Sullivan AK, Mackie N, Reeves I, Portman M, Saunders J, Fox J, Bayley J, Brady M, Bowman C, Lacey CJ, Taylor S, White D, Antonucci S, Gafos M, McCormack S, Gill ON, Dunn DT, Nardone A; PROUD Study Group. Dolling DI, et al. Among authors: clarke a. Trials. 2016 Mar 24;17:163. doi: 10.1186/s13063-016-1286-4. Trials. 2016. PMID: 27013513 Free PMC article. Clinical Trial.
Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.
Arenas-Pinto A, Stöhr W, Jäger HR, Haddow L, Clarke A, Johnson M, Chen F, Winston A, Godi C, Thust S, Trombin R, Cairns J, Solanky BS, Golay X, Paton NI; PIVOT Neurocognitive sub-study Team. Arenas-Pinto A, et al. Among authors: clarke a. Clin Infect Dis. 2016 Jul 15;63(2):257-64. doi: 10.1093/cid/ciw279. Epub 2016 May 3. Clin Infect Dis. 2016. PMID: 27143662 Free PMC article. Clinical Trial.
Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy.
Stöhr W, Dunn DT, Arenas-Pinto A, Orkin C, Clarke A, Williams I, Johnson M, Beeching NJ, Wilkins E, Sanders K, Paton NI; Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team. Stöhr W, et al. Among authors: clarke a. AIDS. 2016 Nov 13;30(17):2617-2624. doi: 10.1097/QAD.0000000000001206. AIDS. 2016. PMID: 27456983 Clinical Trial.
Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
Kunisaki KM, Niewoehner DE, Collins G, Aagaard B, Atako NB, Bakowska E, Clarke A, Corbelli GM, Ekong E, Emery S, Finley EB, Florence E, Infante RM, Kityo CM, Madero JS, Nixon DE, Tedaldi E, Vestbo J, Wood R, Connett JE; INSIGHT START Pulmonary Substudy Group. Kunisaki KM, et al. Among authors: clarke a. Lancet Respir Med. 2016 Dec;4(12):980-989. doi: 10.1016/S2213-2600(16)30319-8. Epub 2016 Oct 20. Lancet Respir Med. 2016. PMID: 27773665 Free PMC article. Clinical Trial.
Evaluation of cerebrospinal fluid virological escape in patients on long-term protease inhibitor monotherapy.
Arenas-Pinto A, Stöhr W, Clarke A, Williams I, Beeching NJ, Minton J, Lee V, Paton NI; Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) CNS sub-study Team. Arenas-Pinto A, et al. Among authors: clarke a. Antivir Ther. 2017;22(6):535-538. doi: 10.3851/IMP3146. Epub 2017 Feb 24. Antivir Ther. 2017. PMID: 28234235 Free PMC article.
3,902 results